FACTORS ASSOCIATED WITH EARLY OUTCOMES AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS AGED ≥75 YEARS WITH ST-ELEVATION MYOCARDIAL INFARCTION
Nội dung chính của bài viết
Tóm tắt
Objective: To evaluate several factors affecting the outcome of percutaneous coronary intervention (PCI) within 30 days in patients aged ≥75 years with ST-elevation myocardial infarction (STEMI).
Subjects and Methods: A cross-sectional descriptive study was conducted on 104 patients aged ≥75 years who were diagnosed with ST-elevation myocardial infarction (STEMI) and indicated for primary percutaneous coronary intervention (PCI) at the Vietnam National Heart Institute – Bach Mai Hospital, Hanoi Heart Hospital, and Huu Nghi Hospital from 2018 to 2021.
Results: The incidence of major adverse cardiovascular events (MACE) was 10.6%. Age ≥85 years (OR = 5.37; p = 0.006), Killip class III and IV (OR = 4.74; p = 0.028), TIMI score >6 (OR = 9.79; p = 0.011), CK-MB >39 U/L (OR = 4.11; p = 0.032), elevated Troponin T >4084.2 ng/L (OR = 6.19; p = 0.008), and ST elevation ≥4.0 mm (OR = 6.24; p = 0.003) were associated with an increased risk of MACE within 30 days after primary PCI in elderly patients.
Conclusion: Factors associated with adverse outcomes after primary PCI in patients aged ≥75 years with STEMI within 30 days included advanced age, high Killip class, TIMI score >6, elevated CK-MB, Troponin T levels, and ST elevation ≥4.0 mm.
Chi tiết bài viết
Từ khóa
Primary coronary intervention, myocardial infarction, ST elevation, ≥75 years old.
Tài liệu tham khảo
[2] Nguyen Quang Tuan (2011). Percutaneous Coronary Intervention in the Treatment of Acute Myocardial Infarction: Methods, Research Results, Efficacy, and Prognosis. Hanoi: Medical Publishing House.
[3] Garcia-Garcia H. M., McFadden E. P., Farb A., et al. (2018). Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. European Heart Journal, 39(23): 2192-2207.
[4] Thygesen K., Alpert J. S., Jaffe A. S., et al. (2018). Fourth Universal Definition of Myocardial Infarction (2018). Circulation, 138(20): e618-e651.
[5] Lansky A. J., Messé S. R., Brickman A. M., et al. (2018). Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. Eur Heart J, 39(19): 1687-1697.
[6] Gharacholou S. M., Lopes R. D., Alexander K. P., et al. (2011). Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial. Archives of internal medicine, 171(6): 559-567.
[7] Taguchi E., Konami Y., Inoue M., et al. (2017). Impact of Killip classification on acute myocardial infarction: data from the SAIKUMA registry. Heart Vessels, 32(12): 1439-1447.
[8] Antman E. M., Cohen M., Bernink P. J., et al. (2000). The TIMI risk score for unstable angina/non–ST elevation MI: a method for prognostication and therapeutic decision making. Jama, 284(7): 835-842.
[9] Apple F. S., Quist H. E., Otto A. P., et al. (2002). Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clinical Chemistry, 48(7): 1097-1100.
[10] De Filippis A. P., Chapman A. R., Mills N. L., et al. (2019). Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury. Circulation, 140(20): 1661-1678.
[11] Nguyen Huy Loi, Pham Manh Hung, Duong Dinh Chinh (2023). Current status and some factors affecting the outcomes of emergency percutaneous coronary intervention in patients with ST-elevation myocardial infarction at Nghe An Friendship General Hospital. Journal of Medical Research, 162(1): 237-246.